Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have received an average recommendation of "Buy" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $59.20.

Several research analysts have weighed in on ARCT shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a report on Thursday, April 10th. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Finally, Canaccord Genuity Group cut their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research note on Monday, March 10th.

Arcturus Therapeutics Trading Up 2.6 %

ARCT stock traded up $0.33 on Tuesday, hitting $12.83. The company had a trading volume of 240,286 shares, compared to its average volume of 449,659. Arcturus Therapeutics has a 12-month low of $8.04 and a 12-month high of $45.00. The stock has a market cap of $347.96 million, a price-to-earnings ratio of -5.78 and a beta of 3.41. The stock's 50-day simple moving average is $12.35 and its 200 day simple moving average is $15.74.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to the consensus estimate of $44.64 million. Research analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Several institutional investors have recently made changes to their positions in the business. Balyasny Asset Management L.P. bought a new position in Arcturus Therapeutics in the 4th quarter worth approximately $9,312,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock worth $14,409,000 after buying an additional 479,482 shares in the last quarter. J. Goldman & Co LP bought a new position in shares of Arcturus Therapeutics during the fourth quarter worth $5,024,000. MPM Bioimpact LLC grew its stake in Arcturus Therapeutics by 109.5% during the fourth quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company's stock valued at $7,805,000 after acquiring an additional 240,435 shares in the last quarter. Finally, Empire Life Investments Inc. increased its holdings in Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock valued at $4,742,000 after acquiring an additional 128,771 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.